tradingkey.logo
搜索

Beta Bionics Inc

BBNX
添加自选
21.710USD
-0.480-2.16%
收盘 09-23 16:00(美东)
976.73M总市值
亏损市盈率 TTM

关于 Beta Bionics Inc 公司

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc 简介

公司代码BBNX
公司名称Beta Bionics Inc
上市日期Jan 30, 2025
CEOSaint (Sean)
员工数量291
证券类型Ordinary Share
年结日Jan 30
公司地址11 Hughes
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92618
电话19494277785
网址https://www.betabionics.com
公司代码BBNX
上市日期Jan 30, 2025
CEOSaint (Sean)

Beta Bionics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
169.63K
-2.49%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
94.35K
-7.27%

常见问题

Beta Bionics Inc的前五大股东是谁?

Beta Bionics Inc 的前五大股东如下:Dr. Steven Russell, M.D., Ph.D.

有多少机构持有Beta Bionics Inc(BBNX)的股份?

截至2026Q1,共有264家机构持有Beta Bionics Inc的股份,合计持有的股份价值约为49.25M,占公司总股份的110.51%。与2025Q4相比,机构持股有所增加,增幅为-2186348.00。

哪个业务部门对Beta Bionics Inc的收入贡献最大?

在2026Q1,DME channel - iLet业务部门对Beta Bionics Inc的收入贡献最大,创收12.65M,占总收入的39.52%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有